Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-02-25
2009-10-13
Desai, Anand U (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000
Reexamination Certificate
active
07601691
ABSTRACT:
The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The present invention also relates to a conjugate comprising such a compound which is covalently bonded to a blood component. Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or functional derivative thereof.
REFERENCES:
patent: 4206199 (1980-06-01), Fujino et al.
patent: 4251631 (1981-02-01), Simon
patent: 4423034 (1983-12-01), Nakagawa et al.
patent: 4462941 (1984-07-01), Lee et al.
patent: 4859604 (1989-08-01), Gould et al.
patent: 5493007 (1996-02-01), Burnier et al.
patent: 5580853 (1996-12-01), Sytkowski
patent: 5612034 (1997-03-01), Pouletty et al.
patent: 5654276 (1997-08-01), Barrett et al.
patent: 5837247 (1998-11-01), Oppenhelm et al.
patent: 5840733 (1998-11-01), Krantz et al.
patent: 5843440 (1998-12-01), Pouletty et al.
patent: 5874408 (1999-02-01), Nayar
patent: 5876969 (1999-03-01), Fleer et al.
patent: 5877151 (1999-03-01), Pereira
patent: 5877204 (1999-03-01), Davison et al.
patent: 5942620 (1999-08-01), Krantz et al.
patent: 6063761 (2000-05-01), Jones et al.
patent: 6087375 (2000-07-01), Bridon et al.
patent: 6103233 (2000-08-01), Pouletty et al.
patent: 6107489 (2000-08-01), Krantz et al.
patent: 6165470 (2000-12-01), Becquart et al.
patent: 6197813 (2001-03-01), Hegenauer
patent: 6277583 (2001-08-01), Krantz et al.
patent: 6277863 (2001-08-01), Krantz et al.
patent: 6329336 (2001-12-01), Bridon et al.
patent: 6342225 (2002-01-01), Jones et al.
patent: 6403324 (2002-06-01), Krantz et al.
patent: 6437092 (2002-08-01), Ezrin et al.
patent: 6440417 (2002-08-01), Thibaudeau et al.
patent: 6500918 (2002-12-01), Ezrin et al.
patent: 6514500 (2003-02-01), Bridon et al.
patent: 6593295 (2003-07-01), Bridon et al.
patent: 6602981 (2003-08-01), Ezrin et al.
patent: 6610825 (2003-08-01), Ezrin et al.
patent: 6706892 (2004-03-01), Ezrin et al.
patent: 6818611 (2004-11-01), Altman
patent: 6887470 (2005-05-01), Bridon et al.
patent: 7090851 (2006-08-01), Boudjellab et al.
patent: 7144854 (2006-12-01), Beliveau et al.
patent: 7256253 (2007-08-01), Bridon et al.
patent: 7307148 (2007-12-01), Bousquet-Gagnon et al.
patent: 2002/0018751 (2002-02-01), Bridon et al.
patent: 2003/0073630 (2003-04-01), Bridon et al.
patent: 2003/0105867 (2003-06-01), Colrain et al.
patent: 2003/0108568 (2003-06-01), Bridon et al.
patent: 2003/0170250 (2003-09-01), Ezrin et al.
patent: 2004/0106589 (2004-06-01), Webb et al.
patent: 2004/0127398 (2004-07-01), Bridon et al.
patent: 2004/0138100 (2004-07-01), Bridon et al.
patent: 2004/0156859 (2004-08-01), Ezrin et al.
patent: 2004/0248782 (2004-12-01), Bridon et al.
patent: 2005/0037974 (2005-02-01), Krantz et al.
patent: 2005/0065075 (2005-03-01), Erickson et al.
patent: 2005/0070475 (2005-03-01), Bridon et al.
patent: 2005/0176643 (2005-08-01), Bridon et al.
patent: 2006/0099571 (2006-05-01), Altman
patent: DD-252539 (1987-12-01), None
patent: 19936780 (2001-02-01), None
patent: 0602290 (1994-06-01), None
patent: 1234586 (2002-08-01), None
patent: 03502691 (1989-08-01), None
patent: 03178998 (1991-08-01), None
patent: 9201476 (1992-02-01), None
patent: WO-93/25217 (1993-12-01), None
patent: 9422467 (1994-10-01), None
patent: WO-95/00534 (1995-01-01), None
patent: WO-95/10302 (1995-04-01), None
patent: WO-96/06626 (1996-03-01), None
patent: 9614854 (1996-05-01), None
patent: 9629342 (1996-09-01), None
patent: WO-96/26544 (1996-09-01), None
patent: WO-97/25074 (1997-07-01), None
patent: WO-97/29372 (1997-08-01), None
patent: WO-98/00171 (1998-01-01), None
patent: 9820885 (1998-05-01), None
patent: WO-99/24074 (1999-05-01), None
patent: WO-99/24075 (1999-05-01), None
patent: WO-99/24076 (1999-05-01), None
patent: WO-99/24462 (1999-05-01), None
patent: WO-99/48534 (1999-09-01), None
patent: WO-99/48536 (1999-09-01), None
patent: WO-00/69900 (2000-11-01), None
patent: WO-00/76550 (2000-12-01), None
patent: WO-00/76551 (2000-12-01), None
patent: 0117568 (2001-03-01), None
patent: 04011498 (2004-02-01), None
patent: 05099768 (2005-10-01), None
patent: 05103087 (2005-11-01), None
patent: 07049941 (2007-05-01), None
patent: 07071068 (2007-06-01), None
Tatemoto, “Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion”, Proc. Natl. Acad. Sci. USA 79: 2514-2518 (1982).
Schechter et al., “Reversible PEGylation of peptide YY(3-36) prolongs its inhibition of food intake in mice”, FEBS Letters 579: 2439-2444 (2005).
U.S. Appl. No. 09/623,633, filed Sep. 5, 2000, Boudjellab et al.
U.S. Appl. No. 09/623,543, filed Sep. 5, 2000, Beliveau et al.
U.S. Appl. No. 09/657,336, filed Sep. 7, 2000, Boudjellab et al.
U.S. Appl. No. 09/657,431, filed Sep. 7, 2000, Beliveau et al.
U.S. Appl. No. 11/066,697, filed Feb. 25, 2005, Bridon et al.
International Search Report mailed Jan. 27, 2004, for PCT patent application No. PCT/CA03/01097 filed on Jul. 29, 2003, 3 pages.
Akil, Huda et al. (1984) “Endogenous Opioids: Biology and Function,” Ann. Rev. Neurosci., 7:223-255.
Breton, Jerome et al. (1995) “Prolonged Half-life in the Circulation of a Chemical Conjugate between a Pro-urokinase Derivative and Human Serum Albumin,” Eur. J. Biochem., 231:563-569.
Brunner-La Rocca, Hans Peter et al. (2001) “Therapeutic Benefits of Increasing Natriuretic Peptide Levels,” Cardiovascular Research, 51:510-520.
Hirai, Yuko et al. (1979) “A New Mast Cell Degranulating Peptide ‘Mastoparan’ in the Venom of Vespula Lewisii,” Chem. Pharm. Bull., 27(8):1942-1944.
Kapas, Supriya et al. (Oct. 1995) “Cloning and Expression of cDNA Encoding a Rat Adrenomedullin Receptor,” J. Biol. Chem., 270(43):25344-25347.
Knusli, Claudio et al. (1992) “Polyethylene Glycol (PEG) Modification of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Enhances Neutroophil Priming Activity but not Colony Stimulating Activity,” British Journal of Haematology, 82:654-663.
Leger, Roger et al. (2003) “Synthesis and In Vitro Analysis of Atrial Natriuetic Peptide-Albumin Conjugates,” Bioorganic & Medicinal Chemistry Letters, 13:3571-3575.
Mumby, Susanne M. et al. (Jan. 1986) “Antisera of Designed Specificity for Subunits of Guanine Nucleotide-Binding Regulatory Proteins,” Proc. Natl. Acad. Sci., 83:265-269.
Oren, Ziv et al. (1998) “Mode of Action of Linear Amphipathic α-Helical Antimicrobial Peptides,” Biopolymers (Peptide Science), 47:451-463.
Otteson, Kenneth M. et al (1983) “Comparisons of Peptide Sequences with Deprotection Problems in Fmoc Solid Phase Peptide Synthesis,” Proceedings of the 8th American Peptide Symposium, pp. 409-412.
Patrias et al. (1994/1995) “Trimethylaminuria (Fish-Malodor Syndrome) and the Flavin Monoxygenases,” Biotech Report pp. 106-107.
Reubi, JC et al. (1982) Endocrinology, 110(3):1049-1051.
Selkoe, Dennis J. (1993) “Physiological Production of the β- Amyloid Protein and the Mechanism of Alzheimer's Disease,” TINS, 16(10):403-409.
Smith, Francine G. et al. (1989) “Atrial Natriuretic Factor During Fetal and Postnatal Life: A Review,” J. Dev. Physiol., 12:55-62.
Stehle, Gerd et al. (1997) “The Loading Rate Determines Tumor Targeting Properties of Methotrexate-Albumin Conjugates in Rats,” Anti-Cancer Drugs, 8:677-685.
Thim, Lars et al. (1998) “Molecules in Focus:CART, a New Anorectic Peptide,” Int. J. Biochem. Cell. Biol., 30:1281-1284.
Ito, K. et al. (Dec. 1995) “Preparation of Specific Antiserum of Secretin and its Use in Time-Resolved FluoroImmunoassay,” Journal of the Pharmaceutical Society of Japan, abstract.
Singer, M. V. et al. (1981) “Effect of Adding Albumin to Solutions of Secretin on Pancreatic Volume and Bicarbonate
Bridon Dominique P.
Huang Xicai
Leger Roger
Milner Peter G.
Robitaille Martin
Conjuchem Biotechnologies Inc.
Desai Anand U
Lando & Anastasi LLP
LandOfFree
Anti-obesity agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-obesity agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-obesity agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4124437